107 results on '"Bordon, V"'
Search Results
2. Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens
- Author
-
Versluys, A. B., Boelens, J. J., Pronk, C., Lankester, A., Bordon, V., Buechner, J., Ifversen, M., Jackmann, N., Sundin, M., Vettenranta, K., Abrahamsson, J., and Mellgren, K.
- Published
- 2021
- Full Text
- View/download PDF
3. A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation
- Author
-
Tavernier, S. J., Athanasopoulos, V., Verloo, P., Behrens, G., Staal, J., Bogaert, D. J., Naesens, L., De Bruyne, M., Van Gassen, S., Parthoens, E., Ellyard, J., Cappello, J., Morris, L. X., Van Gorp, H., Van Isterdael, G., Saeys, Y., Lamkanfi, M., Schelstraete, P., Dehoorne, J., Bordon, V., Van Coster, R., Lambrecht, B. N., Menten, B., Beyaert, R., Vinuesa, C. G., Heissmeyer, V., Dullaers, M., and Haerynck, F.
- Published
- 2019
- Full Text
- View/download PDF
4. Author Correction: A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation
- Author
-
Tavernier, S. J., Athanasopoulos, V., Verloo, P., Behrens, G., Staal, J., Bogaert, D. J., Naesens, L., De Bruyne, M., Van Gassen, S., Parthoens, E., Ellyard, J., Cappello, J., Morris, L. X., Van Gorp, H., Van Isterdael, G., Saeys, Y., Lamkanfi, M., Schelstraete, P., Dehoorne, J., Bordon, V., Van Coster, R., Lambrecht, B. N., Menten, B., Beyaert, R., Vinuesa, C. G., Heissmeyer, V., Dullaers, M., and Haerynck, F.
- Published
- 2019
- Full Text
- View/download PDF
5. Correction: Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens
- Author
-
Versluys, A. B., Boelens, J. J., Pronk, C., Lankester, A., Bordon, V., Buechner, J., Ifversen, M., Jackmann, N., Sundin, M., Vettenranta, K., Abrahamsson, J., and Mellgren, K.
- Published
- 2021
- Full Text
- View/download PDF
6. Additional file 1 of Central nervous system manifestations of LRBA deficiency: case report of two siblings and literature review
- Author
-
Mangodt, T. C., Vanden Driessche, K., Norga, K. K., Moes, N., De Bruyne, M., Haerynck, F., Bordon, V., Jansen, A. C., and Jonckheere, A. I.
- Abstract
Additional file 1: Supplemental figure S1. Diffusion-weighted imaging (DWI; a and b) demonstrating bilateral parieto-occipital cortical diffusion restriction. Apparent diffusion coefficient (ADC; c and d) map confirming diffusion restriction in these regions. Images in conjunction with those in Fig. 2 compatible with PRES. Images from patient P1.
- Published
- 2023
- Full Text
- View/download PDF
7. Additional file 4 of Central nervous system manifestations of LRBA deficiency: case report of two siblings and literature review
- Author
-
Mangodt, T. C., Vanden Driessche, K., Norga, K. K., Moes, N., De Bruyne, M., Haerynck, F., Bordon, V., Jansen, A. C., and Jonckheere, A. I.
- Abstract
Additional file 4: Supplemental figure S4. DWI images (a and b) demonstrating bilateral fronto-parieto-occipital cortical diffusion restriction. ADC map (c and d) confirming diffusion restriction in the cortex of these regions. Images in conjunction with those in Fig. 6 compatible with PRES. Images from patient P2.
- Published
- 2023
- Full Text
- View/download PDF
8. Additional file 2 of Central nervous system manifestations of LRBA deficiency: case report of two siblings and literature review
- Author
-
Mangodt, T. C., Vanden Driessche, K., Norga, K. K., Moes, N., De Bruyne, M., Haerynck, F., Bordon, V., Jansen, A. C., and Jonckheere, A. I.
- Abstract
Additional file 2: Supplemental figure S2. T2-FLAIR hyperintense contrast-enhanced lesions occurring widely spread in the supratentorial (a, b, c, d) and infratentorial (d) grey matter. Note as well the lesions in the lateral part of the right external globus pallidus (c, full arrow) and the left parahippocampal gyrus (d, dashed arrow). As in Fig. 2 and 3, the arachnoidal cyst in the left temporal region can also be observed (c, dashed arrow). Evolution after 6 months of treatment with abatacept can be seen on the follow-up images depicted with (ii), demonstrating global regression of the lesions and decreased contrast enhancement. Images from patient P1.
- Published
- 2023
- Full Text
- View/download PDF
9. Additional file 3 of Central nervous system manifestations of LRBA deficiency: case report of two siblings and literature review
- Author
-
Mangodt, T. C., Vanden Driessche, K., Norga, K. K., Moes, N., De Bruyne, M., Haerynck, F., Bordon, V., Jansen, A. C., and Jonckheere, A. I.
- Abstract
Additional file 3: Supplemental figure S3. Expansive lesion of the cervical spinal medulla from C3-C4 down to Th1-Th2. On the T1-weighted images (a and b) the patchy superficial contrast enhancement can be seen. Evolution after 6 months of treatment with abatacept can be observed on the follow-up images depicted with (ii), demonstrating reduced extent and decreased contrast enhancement. Images from patient P1.
- Published
- 2023
- Full Text
- View/download PDF
10. P47 - Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH GATA2-RELATED MYELODYSPLASTIC SYNDROME
- Author
-
Bortnick, R., Wlodarski, M., De Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Masetti, R., Stary, J., Turkiewicz, D., Ussowicz, M., Kozyra, E., Albert, M., Bader, P., Bordon, V., Cario, G., Beier, R., Schulte, J., Bresters, D., Mueller, I., Pichler, H., Sedlacek, P., Sauer, M., Zecca, M., Göhring, G., Yoshimi, A., Noellke, P., Erlacher, M., Locatelli, F., Niemeyer, C., and Strahm, B.
- Published
- 2021
- Full Text
- View/download PDF
11. Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes
- Author
-
Bortnick, R., primary, Wlodarski, M., additional, De Haas, V., additional, De Moerloose, B., additional, Dworzak, M., additional, Hasle, H., additional, Masetti, R., additional, Stary, J., additional, Turkiewicz, D., additional, Ussowicz, M., additional, Kozyra, E., additional, Albert, M., additional, Bader, P., additional, Bordon, V., additional, Cario, G., additional, Beier, R., additional, Schulte, J., additional, Bresters, D., additional, Mueller, I., additional, Pichler, H., additional, Sedlacek, P., additional, Sauer, M., additional, Zecca, M., additional, Göhring, G., additional, Yoshimi, A., additional, Noellke, P., additional, Erlacher, M., additional, Locatelli, F., additional, Niemeyer, C., additional, and Strahm, B., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study
- Author
-
Strahm, B, Nöllke, P, Zecca, M, Korthof, E T, Bierings, M, Furlan, I, Sedlacek, P, Chybicka, A, Schmugge, M, Bordon, V, Peters, C, O'Marcaigh, A, de Heredia, C D, Bergstraesser, E, Moerloose, B D, van den Heuvel-Eibrink, M M, Starý, J, Trebo, M, Wojcik, D, Niemeyer, C M, and Locatelli, F
- Published
- 2011
- Full Text
- View/download PDF
13. UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR CHILDREN WITH OSTEOPETROSIS: AN EUROCORD AND INBORN ERRORS WORKING PARTY (IEWP)-EBMT STUDY: PH-O067
- Author
-
Chiesa, R., Ruggeri, A., Zecca, M., Gonzales-Vincent, M., Bordon, V., Yaniv, I., Lawson, S., Poire, X., Dini, G., Abecasis, M., Al-Seraihy, A., Kenzey, C., Xavier, E., Bierings, M., Gluckman, E., Locatelli, F., Schulz, A., Gennery, A., and Rocha, V.
- Published
- 2014
14. OUTCOMES OF ALLOGENEIC CORD BLOOD TRANSPLANTATION FOR LEUKODYSTROPHIES; A JOINT STUDY OF EUROCORD AND “INBORN ERRORS WP-EBMT”: PH-O069
- Author
-
Hol, J., Ruggeri, A., Rocha, V., Michel, G., Ayas, M., OʼBrien, T., Krivan, G., Bordon, V., Schots, R., Rovelli, A., Elorza, I., Moraleda, J. M., Shaw, P. J., Renard, M., Sykora, K.-W., Or, R., Zuckerman, T., Abecasis, M., Bredius, R., Yesilipek, A., Diaz, M. A., Gennery, A., Gluckman, E., and Boelens, J. J.
- Published
- 2014
15. Hematopoietic stem cell transplantation for CD40 ligand deficiency : Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study
- Author
-
Ferrua, F., Galimberti, S., Courteille, V., Slatter, M.A., Booth, C., Moshous, D., Neven, B., Blanche, S., Cavazzana, M., Laberko, A., Shcherbina, A., Balashov, D., Soncini, E., Porta, F., Al-Mousa, H., Al-Saud, B., Al-Dhekri, H., Arnaout, R., Formankova, R., Bertrand, Y., Lange, A., Smart, J., Wolska-Kusnierz, B., Aquino, V.M., Dvorak, C.C., Fasth, A., Fouyssac, F., Heilmann, C., Hoenig, M., Schuetz, C., Kelecic, J., Bredius, R.G.M., Lankester, A.C., Lindemans, C.A., Suarez, F., Sullivan, K.E., Albert, M.H., Kalwak, K., Barlogis, V., Bhatia, M., Bordon, V., Czogala, W., Alonso, L., Dogu, F., Gozdzik, J., Ikinciogullari, A., Krivan, G., Ljungman, P., Meyts, I., Mustillo, P., Smith, A.R., Speckmann, C., Sundin, M., Keogh, S.J., Shaw, P.J., Boelens, J.J., Schulz, A.S., Sedlacek, P., Veys, P., Mahlaoui, N., Janda, A., Davies, E.G., Fischer, A., Cowan, M.J., Gennery, A.R., SCETIDE, PIDTC, EBMT, ESID IEWP, Ferrua, F, Galimberti, S, Courteille, V, Slatter, M, Booth, C, Moshous, D, Neven, B, Blanche, S, Laberko, A, Shcherbina, A, Balashov, D, Soncini, E, Porta, F, Al-Mousa, H, Al-Saud, B, Al-Dhekri, H, Arnaout, R, Formankova, R, Bertrand, Y, Lange, A, Smart, J, Wolska-Kusnierz, B, Aquino, V, Dvorak, C, Fasth, A, Fouyssac, F, Heilmann, C, Hoenig, M, Schuetz, C, Kelečić, J, Bredius, R, Lankester, A, Lindemans, C, Suarez, F, Sullivan, K, Albert, M, Kałwak, K, Barlogis, V, Bhatia, M, Bordon, V, Czogala, W, Alonso, L, Dogu, F, Gozdzik, J, Ikinciogullari, A, Kriván, G, Ljungman, P, Meyts, I, Mustillo, P, Smith, A, Speckmann, C, Sundin, M, Keogh, S, Shaw, P, Boelens, J, Schulz, A, Sedlacek, P, Veys, P, Mahlaoui, N, Janda, A, Davies, E, Fischer, A, Cowan, M, and Gennery, A
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Hematopoietic stem cell transplantation ,X-Linked Combined Immunodeficiency Diseases ,primary immunodeficiency ,Donor lymphocyte infusion ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,X-linked hyper-IgM syndrome ,Humans ,Medicine ,Immunology and Allergy ,Risk factor ,Child ,Prospective cohort study ,business.industry ,Infant, Newborn ,Infant ,medicine.disease ,Treatment Outcome ,030104 developmental biology ,medicine.anatomical_structure ,Graft-versus-host disease ,surgical procedures, operative ,Supportive psychotherapy ,Child, Preschool ,hematopoietic stem cell transplantation ,Primary immunodeficiency ,Bone marrow ,CD40 ligand ,business ,030215 immunology - Abstract
BACKGROUND: CD40 ligand (CD40L) deficiency, an X-linked primary immunodeficiency, causes recurrent sinopulmonary, Pneumocystis and Cryptosporidium species infections. Long-term survival with supportive therapy is poor. Currently, the only curative treatment is hematopoietic stem cell transplantation (HSCT). OBJECTIVE: We performed an international collaborative study to improve patients' management, aiming to individualize risk factors and determine optimal HSCT characteristics. METHODS: We retrospectively collected data on 130 patients who underwent HSCT for CD40L deficiency between 1993-2015. We analyzed outcome and variables' relevance with respect to survival and cure. RESULTS: Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%, and 72.3% 5 years after HSCT. Results were better in transplantations performed in 2000 or later and in children less than 10 years old at the time of HSCT. Pre-existing organ damage negatively influenced outcome. Sclerosing cholangitis was the most important risk factor. After 2000, superior OS was achieved with matched donors. Use of myeloablative regimens and HSCT at 2 years or less from diagnosis associated with higher OS and DFS. EFS was best with matched sibling donors, myeloablative conditioning (MAC), and bone marrow-derived stem cells. Most rejections occurred after reduced-intensity or nonmyeloablative conditioning, which associated with poor donor cell engraftment. Mortality occurred mainly early after HSCT, predominantly from infections. Among survivors who ceased immunoglobulin replacement, T-lymphocyte chimerism was 50% or greater donor in 85.2%. CONCLUSION: HSCT is curative in patients with CD40L deficiency, with improved outcome if performed before organ damage development. MAC is associated with better OS, EFS, and DFS. Prospective studies are required to compare the risks of HSCT with those of lifelong supportive therapy. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol:143 issue:6 pages:2238-2253 ispartof: location:United States status: published
- Published
- 2019
16. Shwachman-Diamond Syndrome: frequent misdiagnosis as Jeune Syndrome and other peculiarities
- Author
-
Corveleyn A, Bossuyt X, Bordon V, Vermylen C, Sevenants L, Haerynck F, Schaballie H, Meyts I, Uyttebroeck A, and Renard M
- Subjects
Pediatrics ,RJ1-570 ,Diseases of the musculoskeletal system ,RC925-935 - Published
- 2011
- Full Text
- View/download PDF
17. Highly effective treatment with tacrolimus ointment in an adolescent with oral graft-versus-host disease
- Author
-
Bauters, T., Bordon, V., Van de Velde, V., Van Lancker, S., Robays, H., Benoit, Y., and Laureys, G.
- Published
- 2010
- Full Text
- View/download PDF
18. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease
- Author
-
Bordon, V., Bravo, S., Van Renterghem, L., de Moerloose, B., Benoit, Y., Laureys, G., and Dhooge, C.
- Published
- 2008
19. Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant
- Author
-
Faraci, M., Diesch, T., Labopin, M., Dalissier, A., Lankester, A., Gennery, A., Sundin, M., Uckan-Cetinkaya, D., Bierings, M., Peters, A.M.J., Garwer, M., Schulz, A., Michel, G., Giorgiani, G., Gruhn, B., Locatelli, F., Giardino, S., Uyttebroeck, A., Rialland, F., Itala-Remes, M., Dreger, P., Shaw, P.J., Bordon, V., Schlegel, P.G., Mellgren, K., Moraleda, J.M., Patrick, K., Schneider, P., Jubert, C., Lawitschka, A., Salooja, N., Basak, G.W., Corbacioglu, S., Duarte, R., Bader, P., and Pediat Transplant Complications Wo
- Subjects
Treo ,Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Cyclophosphamide ,Adolescent ,Puberty, Precocious ,Treosulfan ,medicine ,Humans ,pubertal stage ,Child ,Gonads ,Busulfan ,Retrospective Studies ,Transplantation ,business.industry ,Late effect ,Hematopoietic Stem Cell Transplantation ,gonadal damage ,Hematology ,Allografts ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Prepubertal stage ,Child, Preschool ,Female ,busulfan ,treosulfan ,Transplantation Conditioning ,medicine.symptom ,business ,Chemoradiotherapy ,medicine.drug - Abstract
Gonadal impairment is an important late effect with a significant impact on quality of life of transplanted patients. The aim of this study was to compare gonadal function after busulfan (Bu) or treosulfan (Treo) conditioning regimens in pre- and postpubertal children. This retrospective, multicenter study included children transplanted in pediatric European Society for Blood and Marrow Transplantation (EBMT) centers between 1992 and 2012 who did not receive gonadotoxic chemoradiotherapy before the transplant. We evaluated 137 patients transplanted in 25 pediatric EBMT centers. Median age at transplant was 11.04 years (range, 5 to 18); 89 patients were boys and 48 girls. Eighty-nine patients were prepubertal at transplant and 48 postpubertal. One hundred eighteen children received Bu and 19 Treo. A higher proportion of girls treated with Treo in the prepubertal stage reached spontaneous puberty compared with those treated with Bu (P = .02). Spontaneous menarche was more frequent after Treo than after Bu (P < .001). Postpubertal boys and girls treated with Treo had significantly lower luteinizing hormone levels (P = .03 and P = .04, respectively) compared with the Bu group. Frequency of gonadal damage associated with Treo was significantly lower than that observed after Bu. These results need to be confirmed in a larger population.
- Published
- 2019
20. THERAPEUTIC EFFICACY AND SAFETY OF TRANSFUSION OF PATHOGEN-INACTIVATED PLATELETS TO PEDIATRIC PATIENTS: P-369
- Author
-
Van Haute, L., Benoit, Y., Bordon, V., de Moerloose, B., Vandecruys, E., Van Lancker, S., Van Vooren, M., and Vandekerckhove, B.
- Published
- 2006
21. Extramedullary relapse in patients treated by donor lymphocyte infusion for haematological relapse after allogeneic bone marrow transplant
- Author
-
Bordon, V., De Moerloose, B., Vandecruys, E., Dhooge, C., Benoit, Y., and Laureys, G.
- Published
- 2005
22. Cytomegalovirus surveillance in paediatric patients under allogeneic stem cell transplantation: a single centre experience
- Author
-
Bravo, S., Bordon, V., Van Renterghem, L., Laureys, G., Dhooge, C., and Benoit, Y.
- Published
- 2004
23. Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation
- Author
-
Gluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Simoes, B. P., Ferster, A., Dupont, S., De La Fuente, J., Dalle, J. -H., Zecca, M., Walters, M. C., Krishnamurti, L., Bhatia, M., Leung, K., Yanik, G., Kurtzberg, J., Dhedin, N., Kuentz, M., Michel, G., Apperley, J., Lutz, P., Neven, B., Bertrand, Y., Vannier, J. P., Ayas, M., Cavazzana, M., Matthes-Martin, S., Rocha, V., Elayoubi, H., Kenzey, C., Bader, P., Locatelli, Franco, Ruggeri, A., Eapen, M., Bordon, V., Labarque, V., Pereira, M., Bittencourt, H., Petersen, H., Deconninck, E., Jubert, C., Perrin, J., Cahn, J. Y., Bruno, B., Bordigoni, P., Mechinaud, F., Vernant, J. P., Stephan, J. L., Suttorp, M., Strahm, B., Da Cunha, C. B., Garwer, B., Rothmayer, M., Wendelin, K., Graphakos, S., Tbakhi, A., Naeimi, N., Zuckerman, T., Sharon, P. B., Yaniv, I., Amos, T., Prete, A., Lo Nigro, L., Lanino, E., Faraci, M., Ciceri, F., Marktel, S., De Simone, G., Messina, C., Bartolomeo, P. D. I., Santarone, S., Vallisa, D., Bertaina, A., Arcese, W., Foa, R., Berger, M., Maximova, N., Wallet, S., Bazuaye, G. N., Maschan, A., De Heredia, C. D., Bieler, C. B., Pato, J. R., Heras, I., Trevor, R., Abayomi, K., Thomson, J., Fasth, A., Frodin, U., Ljugman, P., Ansari, M., Gungor, T., Unal, E., Pehlivan, M., Anak, S., Ozturk, G., Unal, A., Lawson, S., Keshani, J., Drake, A., Wynn, R., Williams, J., Jagsia, M., Leung, W., Abraham, A., Sahdey, I., Margolis, D., Eames, G., Horwitz, E., Cowan, M., Kapoor, N., Rowley, S., Megason, G., Rogers, Z., Bolanos-Meade, J., Hudspeth, M., Rosenthal, J., Olson, T., Kassow, K., Selby, G., Haines, H., Chaudhury, S., Gluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Simoes, B. P., Ferster, A., Dupont, S., De La Fuente, J., Dalle, J. -H., Zecca, M., Walters, M. C., Krishnamurti, L., Bhatia, M., Leung, K., Yanik, G., Kurtzberg, J., Dhedin, N., Kuentz, M., Michel, G., Apperley, J., Lutz, P., Neven, B., Bertrand, Y., Vannier, J. P., Ayas, M., Cavazzana, M., Matthes-Martin, S., Rocha, V., Elayoubi, H., Kenzey, C., Bader, P., Locatelli, F., Ruggeri, A., Eapen, M., Bordon, V., Labarque, V., Pereira, M., Bittencourt, H., Petersen, H., Deconninck, E., Jubert, C., Perrin, J., Cahn, J. Y., Bruno, B., Bordigoni, P., Mechinaud, F., Vernant, J. P., Stephan, J. L., Suttorp, M., Strahm, B., Da Cunha, C. B., Garwer, B., Rothmayer, M., Wendelin, K., Graphakos, S., Tbakhi, A., Naeimi, N., Zuckerman, T., Sharon, P. B., Yaniv, I., Amos, T., Prete, A., Lo Nigro, L., Lanino, E., Faraci, M., Ciceri, F., Marktel, S., De Simone, G., Messina, C., Bartolomeo, P. D. I., Santarone, S., Vallisa, D., Bertaina, A., Arcese, W., Foa, R., Berger, M., Maximova, N., Wallet, S., Bazuaye, G. N., Maschan, A., De Heredia, C. D., Bieler, C. B., Pato, J. R., Heras, I., Trevor, R., Abayomi, K., Thomson, J., Fasth, A., Frodin, U., Ljugman, P., Ansari, M., Gungor, T., Unal, E., Pehlivan, M., Anak, S., Ozturk, G., Unal, A., Lawson, S., Keshani, J., Drake, A., Wynn, R., Williams, J., Jagsia, M., Leung, W., Abraham, A., Sahdey, I., Margolis, D., Eames, G., Horwitz, E., Cowan, M., Kapoor, N., Rowley, S., Megason, G., Rogers, Z., Bolanos-Meade, J., Hudspeth, M., Rosenthal, J., Olson, T., Kassow, K., Selby, G., Haines, H., Chaudhury, S., France Monacord, Centre Scientifique de Monaco (CSM), CHI Créteil, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Eurocord, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Universitaire des Enfants - Reine Fabiola, Université Libre de Bruxelles, Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière (NEMESIS-CRICM), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Unité d'Hémato-Immunologie pédiatrique [Hôpital Robert Debré, Paris], Service d'Immuno-hématologie pédiatrique [Hôpital Robert Debré, Paris], Hôpital Robert Debré-Hôpital Robert Debré, Duke University Medical Center, Service de Greffe de Moelle - Unité AJA, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital de la Timone [CHU - APHM] (TIMONE), Department of Haematology, Hôpital Civil, Hopital Civil, Département d'Immunologie, hématologie et rhumatologie pédiatriques [Hôpital Necker-Enfants malades - APHP], CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hemostase, Endothelium, Angiogenese (UMR_S_553), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Churchill Hospital [Breast Care Unit], Churchill Hospital Oxford Centre for Haematology, Santa Lucia Foundation, IRCSS, Rome, Medical College of Wisconsin, National Institute for Health Research, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Universitaire d'Hématologie (IUH), Hôpital Universitaire des Enfants Reine Fabiola [Bruxelles, Belgique] (HUDERF), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique
- Subjects
Male ,HYDROXYUREA ,Transplantation Conditioning ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,CHILDREN ,Hematopoietic stem cell transplantation ,Biochemistry ,THALASSEMIA ,0302 clinical medicine ,HLA Antigens ,Surveys and Questionnaires ,1114 Paediatrics And Reproductive Medicine ,Child ,ComputingMilieux_MISCELLANEOUS ,CÉLULAS-TRONCO ,Hazard ratio ,Graft Survival ,BONE-MARROW TRANSPLANT ,Hematopoietic Stem Cell Transplantation ,Hematology ,Sickle cell anemia ,3. Good health ,Survival Rate ,medicine.anatomical_structure ,Treatment Outcome ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,030220 oncology & carcinogenesis ,Child, Preschool ,Histocompatibility ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Life Sciences & Biomedicine ,medicine.medical_specialty ,Adolescent ,Anemia ,Immunology ,Anemia, Sickle Cell ,1102 Cardiovascular Medicine And Haematology ,Disease-Free Survival ,03 medical and health sciences ,Internal medicine ,MANAGEMENT ,medicine ,Humans ,ANEMIA ,Survival rate ,Transplantation ,Science & Technology ,business.industry ,Siblings ,Sickle cell disease ,Infant ,1103 Clinical Sciences ,ADULTS ,Cell Biology ,medicine.disease ,LIFE ,EXPERT PANEL ,Bone marrow ,FOLLOW-UP ,business ,030215 immunology - Abstract
Despite advances in supportive therapy to prevent complications of sickle cell disease (SCD), access to care is not universal. Hematopoietic cell transplantation is, to date, the only curative therapy for SCD, but its application is limited by availability of a suitable HLA-matched donor and lack of awareness of the benefits of transplant. Included in this study are 1000 recipients of HLA-identical sibling transplants performed between 1986 and 2013 and reported to the European Society for Blood and Marrow Transplantation, Eurocord, and the Center for International Blood and Marrow Transplant Research. The primary endpoint was event-free survival, defined as being alive without graft failure; risk factors were studied using a Cox regression models. The median age at transplantation was 9 years, and the median follow-up was longer than 5 years. Most patients received a myeloablative conditioning regimen (n = 873; 87%); the remainder received reduced-intensity conditioning regimens (n = 125; 13%). Bone marrow was the predominant stem cell source (n = 839; 84%); peripheral blood and cord blood progenitors were used in 73 (7%) and 88 (9%) patients, respectively. The 5-year event-free survival and overall survival were 91.4% (95% confidence interval, 89.6%-93.3%) and 92.9% (95% confidence interval, 91.1%-94.6%), respectively. Event-free survival was lower with increasing age at transplantation (hazard ratio [HR], 1.09; P < .001) and higher for transplantations performed after 2006 (HR, 0.95; P = .013). Twenty-three patients experienced graft failure, and 70 patients (7%) died, with the most common cause of death being infection. The excellent outcome of a cohort transplanted over the course of 3 decades confirms the role of HLA-identical sibling transplantation for children and adults with SCD.
- Published
- 2017
24. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study
- Author
-
Barzaghi, F., Hernandez, L.C.A., Neven, B., Ricci, S., Kucuk, Z.Y., Bleesing, J.J., Nademi, Z., Slatter, M.A., Ulloa, E.R., Shcherbina, A., Roppelt, A., Worth, A., Silva, J., Aiuti, A., Murguia-Favela, L., Speckmann, C., Carneiro-Sampaio, M., Fernandes, J.F., Baris, S., Ozen, A., Karakoc-Aydiner, E., Kiykim, A., Schulz, A., Steinmann, S., Notarangelo, L.D., Gambineri, E., Lionetti, P., Shearer, W.T., Forbes, L.R., Martinez, C., Moshous, D., Blanche, S., Fisher, A., Ruemmele, F.M., Tissandier, C., Ouachee-Chardin, M., Rieux-Laucat, F., Cavazzana, M., Qasim, W., Lucarelli, B., Albert, M.H., Kobayashi, I., Alonso, L., Heredia, C.D. de, Kanegane, H., Lawitschka, A., Seo, J.J., Gonzalez-Vicent, M., Diaz, M.A., Goyal, R.K., Sauer, M.G., Yesilipek, A., Kim, M., Yilmaz-Demirdag, Y., Bhatia, M., Khlevner, J., Padilla, E.J.R., Martino, S., Montin, D., Neth, O., Molinos-Quintana, A., Valverde-Fernandez, J., Broides, A., Pinsk, V., Ballauf, A., Haerynck, F., Bordon, V., Dhooge, C., Garcia-Lloret, M.L., Bredius, R.G., Kawak, K., Haddad, E., Seidel, M.G., Duckers, G., Pai, S.Y., Dvorak, C.C., Ehl, S., Locatelli, F., Goldman, F., Gennery, A.R., Cowan, M.J., Roncarolo, M.G., Bacchetta, R., PIDTC, IEWP, European Soc Blood Marrow, Barzaghi, Federica, Hernandez, Laura Cristina Amaya, Neven, Benedicte, Ricci, Silvia, Kucuk, Zeynep Yesim, Bleesing, Jack J., Nademi, Zohreh, Slatter, Mary Anne, Ulloa, Erlinda Rose, Shcherbina, Anna, Roppelt, Anna, Worth, Austen, Silva, Juliana, Aiuti, Alessandro, Murguia-Favela, Luis, Speckmann, Carsten, Carneiro-Sampaio, Magda, Fernandes, Juliana Folloni, Baris, Safa, Ozen, Ahmet, Karakoc-Aydiner, Elif, Kiykim, Ayca, Schulz, Ansgar, Steinmann, Sandra, Notarangelo, Lucia Dora, Gambineri, Eleonora, Lionetti, Paolo, Shearer, William Thomas, Forbes, Lisa R., Martinez, Caridad, Moshous, Despina, Blanche, Stephane, Fisher, Alain, Ruemmele, Frank M., Tissandier, Come, Ouachee-Chardin, Marie, Rieux-Laucat, Frederic, Cavazzana, Marina, Qasim, Waseem, Lucarelli, Barbarella, Albert, Michael H., Kobayashi, Ichiro, Alonso, Laura, De Heredia, Cristina Diaz, Kanegane, Hirokazu, Lawitschka, Anita, Seo, Jong Jin, Gonzalez-Vicent, Marta, Diaz, Miguel Angel, Goyal, Rakesh Kumar, Sauer, Martin G., Yesilipek, Akif, Kim, Minsoo, Yilmaz-Demirdag, Yesim, Bhatia, Monica, Khlevner, Julie, Padilla, Erick J. Richmond, Martino, Silvana, Montin, Davide, Neth, Olaf, Molinos-Quintana, Agueda, Valverde-Fernandez, Justo, Broides, Arnon, Pinsk, Vered, Ballauf, Antje, Haerynck, Filomeen, Bordon, Victoria, Dhooge, Catharina, Garcia-Lloret, Maria Laura, Bredius, Robbert G., Kalwak, Krzysztof, Haddad, Elie, Seidel, Markus Gerhard, Duckers, Gregor, Pai, Sung-Yun, Dvorak, Christopher C., Ehl, Stephan, Locatelli, Franco, Goldman, Frederick, Gennery, Andrew Richard, Cowan, Mort J., Roncarolo, Maria-Grazia, Bacchetta, Rosa, Amaya Hernandez, Laura Cristina, Murguia-Favela, Lui, Shearer, William Thoma, Rieux-Laucat, Frédéric, Diaz De Heredia, Cristina, Richmond Padilla, Erick J., and Kałwak, Krzysztof
- Subjects
0301 basic medicine ,Male ,Allergy ,medicine.medical_treatment ,Medizin ,Disease ,Hematopoietic stem cell transplantation ,SIROLIMUS ,Regenerative Medicine ,primary immune deficiency ,Medicine and Health Sciences ,IPEX ,Immunology and Allergy ,2.1 Biological and endogenous factors ,Enteropathy ,Aetiology ,POLYENDOCRINOPATHY ,Child ,Pediatric ,CÉLULAS-TRONCO ,immunosuppression ,Hematopoietic Stem Cell Transplantation ,Genetic Diseases, X-Linked ,Immunosuppression ,Forkhead Transcription Factors ,X-LINKED SYNDROME ,Allografts ,Survival Rate ,surgical procedures, operative ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Immune System Diseases ,Genetic Diseases ,Child, Preschool ,hematopoietic stem cell transplantation ,Female ,hematopoietic stem ,neonatal diabetes ,FOXP3 ,Primary Immune Deficiency ,Treg cells ,enteropathy ,genetic autoimmunity ,rapamycin ,Type 1 ,Diarrhea ,Adult ,medicine.medical_specialty ,Adolescent ,Immunology ,Neonatal onset ,Article ,Disease-Free Survival ,03 medical and health sciences ,Neonatal diabete ,Clinical Research ,Internal medicine ,IMMUNODYSREGULATION ,medicine ,Primary Immune Deficiency Treatment Consortium (PIDTC) and the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation ,Diabetes Mellitus ,Genetics ,Humans ,REGULATORY T-CELLS ,cell transplantation ,Preschool ,Retrospective Studies ,Immunosuppression Therapy ,Transplantation ,IMMUNE DYSREGULATION ,business.industry ,MUTATIONS ,Infant ,Retrospective cohort study ,STEM-CELL TRANSPLANTATION ,IPEX syndrome ,X-Linked ,medicine.disease ,Stem Cell Research ,BONE-MARROW-TRANSPLANTATION ,Treg cell ,FOXP3 MUTATIONS ,Diabetes Mellitus, Type 1 ,030104 developmental biology ,ENGRAFTMENT ,Mutation ,business ,Follow-Up Studies - Abstract
Background Immunodysregulation polyendocrinopathy enteropathy x-linked(IPEX) syndromeis a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined. Objective This analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors. Methods Clinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed. Results We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS. Conclusions Patients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen., GRAPHICAL ABSTRACT
- Published
- 2018
25. PF677 DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)
- Author
-
Niemeyer, C.M., primary, Flotho, C., additional, Lipka, D.B., additional, Buechner, J., additional, Catala, A., additional, De Haas, V., additional, De Moerloose, B., additional, Dworzak, M., additional, Fabri, O., additional, Hasle, H., additional, Jahnukainen, K., additional, Kállay, K., additional, Masetti, R., additional, Schmugge, M., additional, Smith, O.P., additional, Stary, J., additional, Turkiewicz, D., additional, Ussowicz, M., additional, Schoenung, M., additional, Erlacher, M., additional, Yoshimi, A., additional, Bierings, M., additional, Bordon, V., additional, Diaz-de-Heredia, C., additional, Horakova, J., additional, Lankaster, A.C., additional, Masmas, T., additional, Meisel, R., additional, O’Marcaigh, A., additional, Roessig, C., additional, Peters, A., additional, Pichler, H., additional, Sauer, M., additional, Sedlacek, P., additional, Zecca, M., additional, Noellke, P., additional, Strahm, B., additional, and Locatelli, F., additional
- Published
- 2019
- Full Text
- View/download PDF
26. Haematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT Inborn Errors Working Party (IEWP) study
- Author
-
Ferrua, F., Courteille, V., Janda, A., Slatter, M., Albert, M.H., Al-Mousa, H., Al-Saud, B., Balashov, D., Bertrand, Y., Booth, C., Bordon, V., Czogala, W., Dogu, F., Fasth, A., Formankova, R., Gozdzik, J., Heilmann, C., Honig, M., Ikinciogullari, A., Kalwak, K., Keogh, S.J., Krivan, G., Lange, A., Lankester, A.C., Ljungman, P., Meyts, I., Neven, B., Soncini, E., Suarez, F., Mahlaoui, N., Fischer, A., Davies, E.G., Gennery, A.R., and EBMT IEWP
- Published
- 2015
27. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency
- Author
-
Hassan, A., Booth, C., Brightwell, A., Allwood, Z., Veys, P., Rao, K., Honig, M., Friedrich, W., Gennery, A., Slatter, M., Bredius, R., Finocchi, A., Cancrini, C., Aiuti, A., Porta, F., Lanfranchi, A., Ridella, M., Steward, C., Filipovich, A., Marsh, R., Bordon, V., Al-Muhsen, S., Al-Mousa, H., Alsum, Z., Al-Dhekri, H., Ghonaium, A. al, Speckmann, C., Fischer, A., Mahlaoui, N., Nichols, K.E., Grunebaum, E., Zahrani, D. al, Roifman, C.M., Boelens, J., Davies, E.G., Cavazzana-Calvo, M., Notarangelo, L., Gaspar, H.B., European Grp Blood Marrow Transpla, European Soc Immunodeficiency, Hassan, A, Booth, C, Brightwell, A, Allwood, Z, Veys, P, Rao, K, Hönig, M, Friedrich, W, Gennery, A, Slatter, M, Bredius, R, Finocchi, A, Cancrini, C, Aiuti, Alessandro, Porta, F, Lanfranchi, A, Ridella, M, Steward, C, Filipovich, A, Marsh, R, Bordon, V, AL MUHSEN, S, AL MOUSA, H, Alsum, Z, AL DHEKRI, H, AL GHONAIUM, A, Speckmann, C, Fischer, A, Mahlaoui, N, Nichols, Ke, Grunebaum, E, AL ZAHRANI, D, Roifman, Cm, Boelens, J, Davies, Eg, CAVAZZANA CALVO, M, Notarangelo, L, and Gaspar, Hb
- Subjects
Oncology ,Male ,Transplantation Conditioning ,Adenosine Deaminase ,Genetic enhancement ,medicine.medical_treatment ,T-Lymphocytes ,Hematopoietic stem cell transplantation ,Kaplan-Meier Estimate ,Biochemistry ,humoral ,Adenosine deaminase ,newborn ,immune system diseases ,Agammaglobulinemia ,hemic and lymphatic diseases ,Child ,Immunity, Cellular ,Hematology ,biology ,Histocompatibility Testing ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,surgical procedures, operative ,Treatment Outcome ,Child, Preschool ,Female ,Unrelated Donors ,medicine.medical_specialty ,Immunology ,preschool ,Internal medicine ,medicine ,Humans ,Lymphocyte Count ,Retrospective Studies ,Settore MED/38 - Pediatria Generale e Specialistica ,Severe combined immunodeficiency ,agammaglobulinemia ,transplantation conditioning ,severe combined immunodeficiency ,humans ,retrospective studies ,infant, newborn ,child ,child, preschool ,kaplan-meier estimate ,infant ,lymphocyte count ,histocompatibility testing ,immunity, cellular ,unrelated donors ,graft survival ,treatment outcome ,myeloablative agonists ,hematopoietic stem cell transplantation ,siblings ,adenosine deaminase ,male ,female ,t-lymphocytes ,immunity, humoral ,business.industry ,Siblings ,Infant, Newborn ,Infant ,Cell Biology ,Myeloablative Agonists ,medicine.disease ,immunity ,Adenosine deaminase deficiency ,Immunity, Humoral ,Transplantation ,biology.protein ,Severe Combined Immunodeficiency ,business ,cellular - Abstract
Deficiency of the purine salvage enzyme adenosine deaminase leads to SCID (ADA-SCID). Hematopoietic cell transplantation (HCT) can lead to a permanent cure of SCID; however, little data are available on outcome of HCT for ADA-SCID in particular. In this multicenter retrospective study, we analyzed outcome of HCT in 106 patients with ADA-SCID who received a total of 119 transplants. HCT from matched sibling and family donors (MSDs, MFDs) had significantly better overall survival (86% and 81%) in comparison with HCT from matched unrelated (66%; P < .05) and haploidentical donors (43%; P < .001). Superior overall survival was also seen in patients who received unconditioned transplants in comparison with myeloablative procedures (81% vs 54%; P < .003), although in unconditioned haploidentical donor HCT, nonengraftment was a major problem. Long-term immune recovery showed that regardless of transplant type, overall T-cell numbers were similar, although a faster rate of T-cell recovery was observed after MSD/MFD HCT. Humoral immunity and donor B-cell engraftment was achieved in nearly all evaluable surviving patients and was seen even after unconditioned HCT. These data detail for the first time the outcomes of HCT for ADA-SCID and show that, if patients survive HCT, long-term cellular and humoral immune recovery is achieved.
- Published
- 2012
28. Multidrug-resistant cytomegalovirus infection in a pediatric stem cell transplantation patient
- Author
-
Bauters, T., primary, Florin, L., additional, Bordon, V., additional, Snoeck, R., additional, Andrei, G., additional, Gillemot, S., additional, Fiten, P., additional, Opdenakker, G., additional, Laureys, G., additional, and Padalko, E., additional
- Published
- 2016
- Full Text
- View/download PDF
29. Erratum: Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction (Science Translational Medicine (2013) 5 (168er1))
- Author
-
Gaspar, H.B. Cooray, S. Gilmour, K.C. Parsley, K.L. Zhang, F. Adams, S. Bjorkegren, E. Bayford, J. Brown, L. Davies, E.G. Veys, P. Fairbanks, L. Bordon, V. Petropoulou, T. Kinnon, C. Thrasher, A.J.
- Published
- 2013
30. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?
- Author
-
Fernandes, Jf, Rocha, V, Labopin, M, Neven, B, Moshous, D, Gennery, Ar, Friedrich, W, Porta, F, Diaz de Heredia, C, Wall, D, Bertrand, Y, Veys, P, Slatter, M, Schulz, A, Chan, Kw, Grimley, M, Ayas, M, Gungor, T, Ebell, W, Bonfim, C, Kalwak, K, Taupin, P, Blanche, S, Gaspar, Hb, Landais, P, Fischer, A, Gluckman, E, Cavazzana Calvo, M, Eurocord, Inborn Errors Working Party of European Group for Blood, Marrow Transplantation: Ahmed, A, Auiti, A, Biffi, A, Cant, A, Fasth, A, Gennery, A, Hassan, A, Lankester, A, O'Mera, A, Plabani, A, Rovelli, A, Salmon, A, Scarselli, A, Thrasher, A, Van Royen, A, Villa, A, Wawer, A, Wahadneh, A, Worth, A, Belohradsky, B, Wolska, B, Gaspar, B, Bonfirm, C, Booth, C, Klein, C, Messina, C, Peters, C, Steward, C, Lindemans, C, Schuetz, C, de Heredia Rubio CD, Bensoussan, D, Gleadow, D, Lilic, D, Gambineri, Eleonora, Smith, E, Aerts, F, Caracseghi, F, Roberts, G, Davies, G, Al Mousa, H, Jossanc, H, Ozsahim, H, Hirsch, I, Meyts, I, Tezcan, I, Mueller, I, Andresc, I, Boelens, J, Fernandes, J, Folloni, J, Keuhl, J, Reichenbach, J, Stary, J, Wachowiak, J, Xu Bayford, J, Cunha, Jm, Ehlert, J, Rao, K, Sykora, K, Andais, L, Brown, L, Dal Cortivo, L, Griffith, L, Notarangelo, L, Abinun, M, Albert, M, Bierings, M, Bouchet, M, Cavazzana, M, Hirschfield, M, Cowan, M, Hoenig, M, Loubser, M, Roncarolo, M, Sauer, M, Schneider, M, Verstegen, M, Schroeder, M, Essink, M, Yesilipek, M, Entz Werle, N, Mahlaoui, N, Schlautmann, N, Taylor, N, Vanroyen, N, Walffraat, N, Sanal, O, Amrolia, P, Bordigoni, P, De Coppi, P, Frange, P, Orchard, P, Sedlacek, P, Shaw, P, Stephensky, P, Bacchetta, R, Bredius, R, Formankova, R, Gale, R, Seger, R, Wynn, R, Corbacioglu, S, Ehl, S, Hacein Bey, S, Hambleton, S, Mohsen, S, Mueller, S, Pai, Sy, Espanol, T, Flood, T, Guengoer, T, Bordon, V, Ormoor, V, Pashano, V, Courteille, V, Czogala, W, Qasim, W, Camci, Y, and Nademi, Z.
- Subjects
Male ,medicine.medical_specialty ,Transplantation Conditioning ,medicine.medical_treatment ,Immunology ,Graft vs Host Disease ,Kaplan-Meier Estimate ,Cord Blood Stem Cell Transplantation ,Hematopoietic stem cell transplantation ,Biochemistry ,Gastroenterology ,SCID HSCT ,Internal medicine ,medicine ,Humans ,Proportional Hazards Models ,Retrospective Studies ,Preparative Regimen ,Severe combined immunodeficiency ,business.industry ,Umbilical Cord Blood Transplantation ,Incidence ,Hematopoietic Stem Cell Transplantation ,Infant, Newborn ,Infant ,Cell Biology ,Hematology ,medicine.disease ,Surgery ,Transplantation ,Treatment Outcome ,Child, Preschool ,Histocompatibility ,Cord blood ,Female ,Severe Combined Immunodeficiency ,business - Abstract
Pediatric patients with SCID constitute medical emergencies. In the absence of an HLA-identical hematopoietic stem cell (HSC) donor, mismatched related-donor transplantation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UCBT) are valuable treatment options. To help transplantation centers choose the best treatment option, we retrospectively compared outcomes after 175 MMRDTs and 74 UCBTs in patients with SCID or Omenn syndrome. Median follow-up time was 83 months and 58 months for UCBT and MMRDT, respectively. Most UCB recipients received a myeloablative conditioning regimen; most MMRDT recipients did not. UCB recipients presented a higher frequency of complete donor chimerism (P = .04) and faster total lymphocyte count recovery (P = .04) without any statistically significance with the preparative regimen they received. The MMRDT and UCBT groups did not differ in terms of T-cell engraftment, CD4+ and CD3+ cell recoveries, while Ig replacement therapy was discontinued sooner after UCBT (adjusted P = .02). There was a trend toward a greater incidence of grades II-IV acute GVHD (P = .06) and more chronic GVHD (P = .03) after UCBT. The estimated 5-year overall survival rates were 62% ± 4% after MMRDT and 57% ± 6% after UCBT. For children with SCID and no HLA-identical sibling donor, both UCBT and MMRDT represent available HSC sources for transplantation with quite similar outcomes.
- Published
- 2012
31. Stem Cell transplantation for lysosomal storage diseases: the Ghent experience
- Author
-
Verloo, P., De Meirleir, Linda, Van Coster, Rudy, Laureys, G., Dhooghe, C., Bordon, V., and Pediatrics
- Subjects
lysosomal storage diseases ,stem cell transplantation - Abstract
Eight patients followed at our centre for a lysosomal storage disease received a hematopoetic stem cell transplantation (four Hurler, three MLD and one Krabbe patient, age at transplantation 8 months to 20 years). Origin of the stem cells was in two cases unrelated cord blood, in three cases bone marrow from a matched unrelated donor (MUD), in two cases peripheral blood from a MUD and in one case bone marrow from a sibling. Both patients transplanted with unrelated cord blood had graft failure (one Hurler, and one infantile MLD). Three other transplanted Hurler patients (two transplanted with bone marrow from a MUD, and one with peripheral blood stem cells from a MUD) had initially normal alfa-L-iduronidase activity, but all evolved to a mixed chimerism with suboptimal alfa-L-iduronidase activity, combined with peripheral disease progression. However, evolution of central nervous pathology is more favorable. Probably remaining alfa-L-iduronidase activity is high enough to protect the brain from further damage and therefore these transplanted patients have a disease progression comparable to Scheie patients. One of these patients is currently under enzyme replacement therapy. Two juvenile MLD patients and one juvenile Krabbe patient have a favorable evolution, with normalization of the enzyme levels. These patients have in common that they were transplanted at an older age. In our small series, patients who were transplanted for slower progressing diseases had better engraftment.
- Published
- 2007
32. Shwachman-Diamond Syndrome: frequent misdiagnosis as Jeune Syndrome and other peculiarities
- Author
-
Meyts, I, primary, Schaballie, H, additional, Haerynck, F, additional, Sevenants, L, additional, Vermylen, C, additional, Bordon, V, additional, Bossuyt, X, additional, Corveleyn, A, additional, Uyttebroeck, A, additional, and Renard, M, additional
- Published
- 2011
- Full Text
- View/download PDF
33. 1FC4.4 Neurological presentation in children with familial and acquired hemophagocytic lymphohistiocytosis
- Author
-
Verhelst, H., primary, Verloo, P., additional, Mondelaers, V., additional, Haerynck, F., additional, Van Coster, R., additional, and Bordon, V., additional
- Published
- 2011
- Full Text
- View/download PDF
34. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease
- Author
-
Bordon, V., primary, Bravo, S., additional, Van Renterghem, L., additional, De Moerloose, B., additional, Benoit, Y., additional, Laureys, G., additional, and Dhooge, C., additional
- Published
- 2007
- Full Text
- View/download PDF
35. A novel Stat1 mutation leading to hyperphosphorylation in a patient with Pneumocystis jjiroveci and chronic mucocutaneous candidiasis
- Author
-
Dullaers, M., Jens Staal, Gerlo, S., Vandermarliere, E., Debacker, V., Bordon, V., Waele, K., Meyts, I., Moens, L., Bossuyt, X., Baets, F., Lambrecht, B. N., Vermaelen, K. Y., and Haerynck, F.
36. Pediatric acute graft-versus-host disease prophylaxis and treatment : surveyed real-life approach reveals dissimilarities compared to published recommendations
- Author
-
Brenda Gibson, Christina Peters, Dorothea Bauer, Isaac Yaniv, Adriana Balduzzi, Brigitte Strahm, Selim Corbacioglu, Roland Meisel, Kim Vettenranta, Cristina Díaz de Heredia, Jacek Wachowiak, Peter Bader, Jean-Hugues Dalle, Arnaud Dalissier, Anita Lawitschka, Giovanna Lucchini, Victoria Bordon, HUS Children and Adolescents, Lastentautien yksikkö, Children's Hospital, University of Helsinki, Lawitschka, A, Lucchini, G, Strahm, B, Dalle, J, Balduzzi, A, Gibson, B, Diaz De Heredia, C, Wachowiak, J, Dalissier, A, Vettenranta, K, Yaniv, I, Bordon, V, Bauer, D, Bader, P, Meisel, R, Peters, C, and Corbacioglu, S
- Subjects
Transplantation Conditioning ,BLOOD ,Graft vs Host Disease ,CHILDREN ,Disease ,030230 surgery ,0302 clinical medicine ,immune system diseases ,Surveys and Questionnaires ,hemic and lymphatic diseases ,Extracorporeal Photopheresis ,Child ,MYCOPHENOLATE-MOFETIL ,Response rate (survey) ,Acute leukemia ,treatment ,Hematopoietic Stem Cell Transplantation ,3. Good health ,surgical procedures, operative ,Acute Disease ,Original Article ,030211 gastroenterology & hepatology ,prophylaxis ,Adult ,medicine.medical_specialty ,pediatrics ,ACUTE GVHD ,03 medical and health sciences ,CENTER STRATEGIES ,Clinical Research ,Internal medicine ,Acute graft versus host disease ,medicine ,Humans ,EXTRACORPOREAL PHOTOPHERESIS ,hematopoietic cell transplantation ,MARROW-TRANSPLANTATION ,ACUTE-LEUKEMIA ,Sibling ,Antilymphocyte Serum ,Transplantation ,EUROPEAN GROUP ,Hematopoietic cell ,business.industry ,prophylaxi ,STEM-CELL TRANSPLANTATION ,3126 Surgery, anesthesiology, intensive care, radiology ,pediatric ,business - Abstract
Pediatric allogeneic hematopoietic cell transplantation (HCT) practices differ from those of adults, particularly the heterogeneity of transplantable nonmalignant diseases and the lower incidence of graft-versus-host disease (GVHD). Several guidelines regarding the management of acute (a) GVHD in adult HCT have been published. We aimed to capture the real-life approaches for pediatric aGVHD prophylaxis/treatment, and data from 75/193 (response rate 39%) EBMT centers (26 countries) were included, representing half (48%) of the pediatric EBMT-HCT activity. Results with >= 75% approval from respondents (74/75) for GVHD prophylaxis after myeloablative HCT for malignancies partially contradict published guidelines: Single-agent cyclosporine A (CsA) was used for matched sibling donor HCT in 47%; blood CsA levels were reported lower; the relapse risk in malignant diseases influenced GVHD prophylaxis with early withdrawal of CsA; distinct longer duration of CsA was employed in nonmalignant diseases. Most centers used additional anti-thymocyte globulin for matched unrelated and mismatched donor HCT, but not for matched siblings. Regarding prophylaxis in nonmyeloablative conditioning (mainly for nonmalignant diseases), responses showed broad heterogeneity. High conformity was found for first-line treatment; however, results regarding steroid-refractory aGVHD indicate an earlier diagnosis in children. Our findings highlight the need for standardized pediatric approaches toward aGVHD prophylaxis/treatment differentiated for malignant and nonmalignant underlying diseases.
- Published
- 2020
37. Macrocephaly? Do not Forget SUFU.
- Author
-
Rijckmans E, Bordon V, de Ravel T, Baert E, Jansen AC, and Stouffs K
- Subjects
- Humans, Repressor Proteins, Megalencephaly diagnosis
- Abstract
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
38. Metachromatic leukodystrophy: To screen or not to screen?
- Author
-
Jonckheere AI, Kingma SDK, Eyskens F, Bordon V, and Jansen AC
- Abstract
Metachromatic leukodystrophy (MLD) is a neurodegenerative lysosomal storage disorder caused by biallelic pathogenic variants in the gene encoding arylsulfatase A. Disease onset is variable (with late infantile, early and late juvenile, and adult forms) and treatment options depend on age and disease symptoms at onset. In the past, allo-hematopoietic stem cell transplantation (allo-HSCT) has been the best treatment option, following strict selection criteria. The outcome however is variable and morbidity remains high. This paved the way to the development of new treatment options, some of them aiming to be curative. In the light of this changing therapeutic field, newborn screening is becoming a valuable option. This narrative review aims to describe the outcome of allo-HSCT in the different MLD disease forms, and, in addition, reviews new treatment options. Finally, the shift of the field towards newborn screening for MLD is discussed., Competing Interests: Declaration of competing interest The authors declare no conflict of interest., (© 2023 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.)
- Published
- 2023
- Full Text
- View/download PDF
39. Comparison of SARS-CoV-2 seroconversion in children with chronic diseases with healthy children and adults during the first waves of the COVID-19 pandemic.
- Author
-
Hoste L, Prytula A, Dehoorne J, De Bruyne R, Van Biervliet S, De Waele K, Maes E, Bordon V, Vanlander A, Claes K, Vande Walle J, Schelstraete P, Van Daele S, and Haerynck F
- Abstract
Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is clinically diverse, and children have a low risk of developing severe coronavirus disease 2019 (COVID-19). However, children with chronic diseases have a potentially increased risk., Methods: We performed a prospective surveillance study with longitudinal serum SARS-CoV-2 anti-nucleocapsid antibody quantification and questionnaires in pediatric tertiary care patients during the first waves of the COVID-19 pandemic (November 2020-September 2021). The results were compared with those of healthy children and adults from the same geographic area., Results: We obtained 525 samples from 362 patients (M/F ratio of 1.3:1; median age of 11.1 years) comprising children with immune-suppressive or immune-modulating drugs (32.9%), inborn errors of immunity (23.5%), type 1 diabetes mellitus (15.2%), and rheumatic diseases (11.9%). A total of 51 (9.7%) samples were seropositive among 37/351 children (10.5%). Seropositivity increased from 5.8% in November-December 2020 to 21.6% in July-September 2021. Compared with adults, a longitudinal analysis revealed reduced seroprevalence but similar kinetics as in children from the same country. Demographic or social variables and disease characteristics did not correlate with seropositivity. Being obese and household contact with COVID-19-infected individuals significantly increased the odds of infection. The majority of seropositive patients had mild symptoms (21/37). One-third were asymptomatic and/or unaware of having COVID-19 (10/37). Four patients (4/37) needed hospitalization, with good clinical outcomes., Conclusions: Although harboring a chronic disease, we observed a low SARS-CoV-2 incidence in a cohort of pediatric tertiary care patients, comparable with healthy children during the first year of the pandemic. Infection was mostly associated with mild symptoms., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Hoste, Prytula, Dehoorne, De Bruyne, Van Biervliet, De Waele, Maes, Bordon, Vanlander, Claes, Vande Walle, Schelstraete, Van daele and Haerynck.)
- Published
- 2023
- Full Text
- View/download PDF
40. Editorial: The role of transcription factors in inborn errors of immunity.
- Author
-
Bogaert DJ, Kuehn HS, Bordon V, and Haerynck F
- Subjects
- Transcription Factors, Trans-Activators
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
41. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study.
- Author
-
Albert MH, Sirait T, Eikema DJ, Bakunina K, Wehr C, Suarez F, Fox ML, Mahlaoui N, Gennery AR, Lankester AC, Beier R, Bernardo ME, Bigley V, Lindemans CA, Burns SO, Carpenter B, Dybko J, Güngör T, Hauck F, Lum SH, Balashov D, Meisel R, Moshous D, Schulz A, Speckmann C, Slatter MA, Strahm B, Uckan-Cetinkaya D, Meyts I, Vallée TC, Wynn R, Neven B, Morris EC, Aiuti A, Maschan A, Aljurf M, Gedde-Dahl T, Gurman G, Bordon V, Kriván G, Locatelli F, Porta F, Valcárcel D, Beguin Y, Faraci M, Kröger N, Kulagin A, Shaw PJ, Veelken JH, Diaz de Heredia C, Fagioli F, Felber M, Gruhn B, Holter W, Rössig C, Sedlacek P, Apperley J, Ayas M, Bodova I, Choi G, Cornelissen JJ, Sirvent A, Khan A, Kupesiz A, Lenhoff S, Ozdogu H, von der Weid N, Rovira M, Schots R, and Vinh DC
- Subjects
- Adolescent, Adult, Child, Humans, Infant, Middle Aged, Retrospective Studies, Transplantation, Homologous, Young Adult, Bronchiectasis etiology, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the gold standard curative therapy for infants and children with many inborn errors of immunity (IEI), but adolescents and adults with IEI are rarely referred for transplant. Lack of published HSCT outcome data outside small, single-center studies and perceived high risk of transplant-related mortality have delayed the adoption of HSCT for IEI patients presenting or developing significant organ damage later in life. This large retrospective, multicenter HSCT outcome study reports on 329 IEI patients (age range, 15-62.5 years at HSCT). Patients underwent first HSCT between 2000 and 2019. Primary endpoints were overall survival (OS) and event-free survival (EFS). We also evaluated the influence of IEI-subgroup and IEI-specific risk factors at HSCT, including infections, bronchiectasis, colitis, malignancy, inflammatory lung disease, splenectomy, hepatic dysfunction, and systemic immunosuppression. At a median follow-up of 44.3 months, the estimated OS at 1 and 5 years post-HSCT for all patients was 78% and 71%, and EFS was 65% and 62%, respectively, with low rates of severe acute (8%) or extensive chronic (7%) graft-versus-host disease. On univariate analysis, OS and EFS were inferior in patients with primary antibody deficiency, bronchiectasis, prior splenectomy, hepatic comorbidity, and higher hematopoietic cell transplant comorbidity index scores. On multivariable analysis, EFS was inferior in those with a higher number of IEI-associated complications. Neither age nor donor had a significant effect on OS or EFS. We have identified age-independent risk factors for adverse outcome, providing much needed evidence to identify which patients are most likely to benefit from HSCT., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
42. Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort.
- Author
-
Lankester AC, Neven B, Mahlaoui N, von Asmuth EGJ, Courteille V, Alligon M, Albert MH, Serra IB, Bader P, Balashov D, Beier R, Bertrand Y, Blanche S, Bordon V, Bredius RG, Cant A, Cavazzana M, Diaz-de-Heredia C, Dogu F, Ehlert K, Entz-Werle N, Fasth A, Ferrua F, Ferster A, Formankova R, Friedrich W, Gonzalez-Vicent M, Gozdzik J, Güngör T, Hoenig M, Ikinciogullari A, Kalwak K, Kansoy S, Kupesiz A, Lanfranchi A, Lindemans CA, Meisel R, Michel G, Miranda NAA, Moraleda J, Moshous D, Pichler H, Rao K, Sedlacek P, Slatter M, Soncini E, Speckmann C, Sundin M, Toren A, Vettenranta K, Worth A, Yeşilipek MA, Zecca M, Porta F, Schulz A, Veys P, Fischer A, and Gennery AR
- Subjects
- Cohort Studies, Humans, Transplantation Conditioning methods, Unrelated Donors, Hematopoietic Stem Cell Transplantation methods, Severe Combined Immunodeficiency genetics, Severe Combined Immunodeficiency therapy
- Abstract
Background: Hematopoietic stem cell transplantation (HSCT) represents a curative treatment for patients with severe combined immunodeficiency (SCID), a group of monogenic immune disorders with an otherwise fatal outcome., Objective: We performed a comprehensive multicenter analysis of genotype-specific HSCT outcome, including detailed analysis of immune reconstitution (IR) and the predictive value for clinical outcome., Methods: HSCT outcome was studied in 338 patients with genetically confirmed SCID who underwent transplantation in 2006-2014 and who were registered in the SCETIDE registry. In a representative subgroup of 152 patients, data on IR and long-term clinical outcome were analyzed., Results: Two-year OS was similar with matched family and unrelated donors and better than mismatched donor HSCT (P < .001). The 2-year event-free survival (EFS) was similar in matched and mismatched unrelated donor and less favorable in mismatched related donor (MMRD) HSCT (P < .001). Genetic subgroups did not differ in 2-year OS (P = .1) and EFS (P = .073). In multivariate analysis, pretransplantation infections and use of MMRDs were associated with less favorable OS and EFS. With a median follow-up of 6.2 years (range, 2.0-11.8 years), 73 of 152 patients in the IR cohort were alive and well without Ig dependency. IL-2 receptor gamma chain/Janus kinase 3/IL-7 receptor-deficient SCID, myeloablative conditioning, matched donor HSCT, and naive CD4 T lymphocytes >0.5 × 10
e3 /μL at +1 year were identified as independent predictors of favorable clinical and immunologic outcome., Conclusion: Recent advances in HSCT in SCID patients have resulted in improved OS and EFS in all genotypes and donor types. To achieve a favorable long-term outcome, treatment strategies should aim for optimal naive CD4 T lymphocyte regeneration., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
43. Familial hemophagocytic lymphohistiocytosis type 3 presenting as neonatal cholestasis and splenomegaly.
- Author
-
Bogaert D, De Bruyne R, Vanlander AV, Garabedian L, Louis Y, Haerynck F, Bordon V, and De Moerloose B
- Subjects
- Humans, Infant, Newborn, Membrane Proteins genetics, Mutation, Splenomegaly, Cholestasis diagnosis, Cholestasis etiology, Lymphohistiocytosis, Hemophagocytic diagnosis
- Published
- 2022
- Full Text
- View/download PDF
44. Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome.
- Author
-
Bortnick R, Wlodarski M, de Haas V, De Moerloose B, Dworzak M, Hasle H, Masetti R, Starý J, Turkiewicz D, Ussowicz M, Kozyra E, Albert M, Bader P, Bordon V, Cario G, Beier R, Schulte J, Bresters D, Müller I, Pichler H, Sedlacek P, Sauer MG, Zecca M, Göhring G, Yoshimi A, Noellke P, Erlacher M, Locatelli F, Niemeyer CM, and Strahm B
- Subjects
- Adolescent, Child, Chromosome Deletion, GATA2 Transcription Factor genetics, Germ-Line Mutation, Humans, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation methods, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes therapy
- Abstract
GATA2 deficiency is a heterogeneous multi-system disorder characterized by a high risk of developing myelodysplastic syndrome (MDS) and myeloid leukemia. We analyzed the outcome of 65 patients reported to the registry of the European Working Group (EWOG) of MDS in childhood carrying a germline GATA2 mutation (GATA2
mut ) who had undergone hematopoietic stem cell transplantation (HSCT). At 5 years the probability of overall survival and disease-free survival (DFS) was 75% and 70%, respectively. Non-relapse mortality and relapse equally contributed to treatment failure. There was no evidence of increased incidence of graft-versus-host-disease or excessive rates of infections or organ toxicities. Advanced disease and monosomy 7 (-7) were associated with worse outcome. Patients with refractory cytopenia of childhood (RCC) and normal karyotype showed an excellent outcome (DFS 90%) compared to RCC and -7 (DFS 67%). Comparing outcome of GATA2mut with GATA2wt patients, there was no difference in DFS in patients with RCC and normal karyotype. The same was true for patients with -7 across morphological subtypes. We demonstrate that HSCT outcome is independent of GATA2 germline mutations in pediatric MDS suggesting the application of standard MDS algorithms and protocols. Our data support considering HSCT early in the course of GATA2 deficiency in young individuals., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
45. A Novel Non-Coding Variant in DCLRE1C Results in Deregulated Splicing and Induces SCID Through the Generation of a Truncated ARTEMIS Protein That Fails to Support V(D)J Recombination and DNA Damage Repair.
- Author
-
Strubbe S, De Bruyne M, Pannicke U, Beyls E, Vandekerckhove B, Leclercq G, De Baere E, Bordon V, Vral A, Schwarz K, Haerynck F, and Taghon T
- Subjects
- Female, Humans, Infant, Mutation, Pedigree, RNA Splicing, DNA Repair genetics, DNA-Binding Proteins genetics, Endonucleases genetics, Severe Combined Immunodeficiency genetics, V(D)J Recombination genetics
- Abstract
Severe Combined Immune Deficiency (SCID) is a primary deficiency of the immune system in which opportunistic and recurring infections are often fatal during neonatal or infant life. SCID is caused by an increasing number of genetic defects that induce an abrogation of T lymphocyte development or function in which B and NK cells might be affected as well. Because of the increased availability and usage of next-generation sequencing (NGS), many novel variants in SCID genes are being identified and cause a heterogeneous disease spectrum. However, the molecular and functional implications of these new variants, of which some are non-coding, are often not characterized in detail. Using targeted NGS, we identified a novel homozygous c.465-1G>C splice acceptor site variant in the DCLRE1C gene in a T
- B- NK+ SCID patient and fully characterized the molecular and functional impact. By performing a minigene splicing reporter assay, we revealed deregulated splicing of the DCLRE1C transcript since a cryptic splice acceptor in exon 7 was employed. This induced a frameshift and the generation of a p.Arg155Serfs*15 premature termination codon (PTC) within all DCLRE1C splice variants, resulting in the absence of full-length ARTEMIS protein. Consistently, a V(D)J recombination assay and a G0 micronucleus assay demonstrated the inability of the predicted mutant ARTEMIS protein to perform V(D)J recombination and DNA damage repair, respectively. Together, these experiments molecularly and functionally clarify how a newly identified c.465-1G>C variant in the DCLRE1C gene is responsible for inducing SCID. In a clinical context, this demonstrates how the experimental validation of new gene variants, that are identified by NGS, can facilitate the diagnosis of SCID which can be vital for implementing appropriate therapies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Strubbe, De Bruyne, Pannicke, Beyls, Vandekerckhove, Leclercq, De Baere, Bordon, Vral, Schwarz, Haerynck and Taghon.)- Published
- 2021
- Full Text
- View/download PDF
46. Thymic Epithelial Cell Alterations and Defective Thymopoiesis Lead to Central and Peripheral Tolerance Perturbation in MHCII Deficiency.
- Author
-
Ferrua F, Bortolomai I, Fontana E, Di Silvestre D, Rigoni R, Marcovecchio GE, Draghici E, Brambilla F, Castiello MC, Delfanti G, Moshous D, Picard C, Taghon T, Bordon V, Schulz AS, Schuetz C, Giliani S, Soresina A, Gennery AR, Signa S, Dávila Saldaña BJ, Delmonte OM, Notarangelo LD, Roifman CM, Poliani PL, Uva P, Mauri PL, Villa A, and Bosticardo M
- Subjects
- Adolescent, Animals, B-Lymphocytes immunology, B-Lymphocytes metabolism, Case-Control Studies, Child, Child, Preschool, Disease Models, Animal, Epithelial Cells metabolism, Europe, Female, Hematopoietic Stem Cell Transplantation, Histocompatibility Antigens Class II genetics, Histocompatibility Antigens Class II metabolism, Homeodomain Proteins genetics, Humans, Infant, Male, Mice, Inbred C57BL, Mice, Knockout, North America, Proteome, Severe Combined Immunodeficiency genetics, Severe Combined Immunodeficiency metabolism, Severe Combined Immunodeficiency surgery, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory metabolism, Thymocytes, Thymus Gland metabolism, Transcriptome, Young Adult, Mice, Epithelial Cells immunology, Histocompatibility Antigens Class II immunology, Immune Tolerance, Severe Combined Immunodeficiency immunology, Thymus Gland immunology
- Abstract
Major Histocompatibility Complex (MHC) class II (MHCII) deficiency (MHCII-D), also known as Bare Lymphocyte Syndrome (BLS), is a rare combined immunodeficiency due to mutations in genes regulating expression of MHCII molecules. MHCII deficiency results in impaired cellular and humoral immune responses, leading to severe infections and autoimmunity. Abnormal cross-talk with developing T cells due to the absence of MHCII expression likely leads to defects in thymic epithelial cells (TEC). However, the contribution of TEC alterations to the pathogenesis of this primary immunodeficiency has not been well characterized to date, in particular in regard to immune dysregulation. To this aim, we have performed an in-depth cellular and molecular characterization of TEC in this disease. We observed an overall perturbation of thymic structure and function in both MHCII
-/- mice and patients. Transcriptomic and proteomic profiling of murine TEC revealed several alterations. In particular, we demonstrated that impairment of lymphostromal cross-talk in the thymus of MHCII-/- mice affects mTEC maturation and promiscuous gene expression and causes defects of central tolerance. Furthermore, we observed peripheral tolerance impairment, likely due to defective Treg cell generation and/or function and B cell tolerance breakdown. Overall, our findings reveal disease-specific TEC defects resulting in perturbation of central tolerance and limiting the potential benefits of hematopoietic stem cell transplantation in MHCII deficiency., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a shared affiliation with one of the authors (CRM)., (Copyright © 2021 Ferrua, Bortolomai, Fontana, Di Silvestre, Rigoni, Marcovecchio, Draghici, Brambilla, Castiello, Delfanti, Moshous, Picard, Taghon, Bordon, Schulz, Schuetz, Giliani, Soresina, Gennery, Signa, Dávila Saldaña, Delmonte, Notarangelo, Roifman, Poliani, Uva, Mauri, Villa and Bosticardo.)- Published
- 2021
- Full Text
- View/download PDF
47. Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations.
- Author
-
Lawitschka A, Lucchini G, Strahm B, Dalle JH, Balduzzi A, Gibson B, Diaz De Heredia C, Wachowiak J, Dalissier A, Vettenranta K, Yaniv I, Bordon V, Bauer D, Bader P, Meisel R, Peters C, and Corbacioglu S
- Subjects
- Acute Disease, Adult, Antilymphocyte Serum, Child, Humans, Surveys and Questionnaires, Transplantation Conditioning, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Pediatric allogeneic hematopoietic cell transplantation (HCT) practices differ from those of adults, particularly the heterogeneity of transplantable nonmalignant diseases and the lower incidence of graft-versus-host disease (GVHD). Several guidelines regarding the management of acute (a) GVHD in adult HCT have been published. We aimed to capture the real-life approaches for pediatric aGVHD prophylaxis/treatment, and data from 75/193 (response rate 39%) EBMT centers (26 countries) were included, representing half (48%) of the pediatric EBMT-HCT activity. Results with ≥75% approval from respondents (74/75) for GVHD prophylaxis after myeloablative HCT for malignancies partially contradict published guidelines: Single-agent cyclosporine A (CsA) was used for matched sibling donor HCT in 47%; blood CsA levels were reported lower; the relapse risk in malignant diseases influenced GVHD prophylaxis with early withdrawal of CsA; distinct longer duration of CsA was employed in nonmalignant diseases. Most centers used additional anti-thymocyte globulin for matched unrelated and mismatched donor HCT, but not for matched siblings. Regarding prophylaxis in nonmyeloablative conditioning (mainly for nonmalignant diseases), responses showed broad heterogeneity. High conformity was found for first-line treatment; however, results regarding steroid-refractory aGVHD indicate an earlier diagnosis in children. Our findings highlight the need for standardized pediatric approaches toward aGVHD prophylaxis/treatment differentiated for malignant and nonmalignant underlying diseases., (© 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.)
- Published
- 2020
- Full Text
- View/download PDF
48. GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner.
- Author
-
Bogaert DJ, Laureys G, Naesens L, Mazure D, De Bruyne M, Hsu AP, Bordon V, Wouters E, Tavernier SJ, Lambrecht BN, De Baere E, Haerynck F, and Kerre T
- Subjects
- Adult, Allografts, Female, GATA2 Deficiency diagnostic imaging, Hematologic Neoplasms diagnostic imaging, Hematologic Neoplasms therapy, Humans, Immunologic Deficiency Syndromes diagnostic imaging, Immunologic Deficiency Syndromes therapy, Male, GATA2 Deficiency therapy, Hematopoietic Stem Cell Transplantation
- Abstract
GATA2 deficiency, first described in 2011, is a bone marrow failure disorder resulting in a complex haematological and immunodeficiency syndrome characterised by cytopenias, severe infections, myelodysplasia and leukaemia. The only curative treatment is allogeneic haematopoietic stem cell transplantation (HSCT). Although knowledge on this syndrome has greatly expanded, in clinical practice many challenges remain. In particular, guidelines on optimal donor and stem cell source and conditioning regimens regarding HSCT are lacking. Additionally, genetic analysis of GATA2 is technically cumbersome and could easily result in false-negative results. With this report, we wish to raise awareness of these pitfalls amongst physicians dealing with haematological malignancies and primary immunodeficiencies., (© 2019 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
49. Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required.
- Author
-
Bauters T, Bordon V, Laureys G, and Dhooge C
- Subjects
- Humans, Nitriles, Pyrimidines, Antineoplastic Combined Chemotherapy Protocols adverse effects, Hypertriglyceridemia chemically induced, Janus Kinases adverse effects, Pyrazoles adverse effects, Sirolimus adverse effects, Triglycerides blood
- Published
- 2019
- Full Text
- View/download PDF
50. Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study.
- Author
-
Ferrua F, Galimberti S, Courteille V, Slatter MA, Booth C, Moshous D, Neven B, Blanche S, Cavazzana M, Laberko A, Shcherbina A, Balashov D, Soncini E, Porta F, Al-Mousa H, Al-Saud B, Al-Dhekri H, Arnaout R, Formankova R, Bertrand Y, Lange A, Smart J, Wolska-Kusnierz B, Aquino VM, Dvorak CC, Fasth A, Fouyssac F, Heilmann C, Hoenig M, Schuetz C, Kelečić J, Bredius RGM, Lankester AC, Lindemans CA, Suarez F, Sullivan KE, Albert MH, Kałwak K, Barlogis V, Bhatia M, Bordon V, Czogala W, Alonso L, Dogu F, Gozdzik J, Ikinciogullari A, Kriván G, Ljungman P, Meyts I, Mustillo P, Smith AR, Speckmann C, Sundin M, Keogh SJ, Shaw PJ, Boelens JJ, Schulz AS, Sedlacek P, Veys P, Mahlaoui N, Janda A, Davies EG, Fischer A, Cowan MJ, and Gennery AR
- Subjects
- Child, Child, Preschool, Humans, Infant, Infant, Newborn, Treatment Outcome, X-Linked Combined Immunodeficiency Diseases mortality, CD40 Ligand deficiency, Hematopoietic Stem Cell Transplantation, X-Linked Combined Immunodeficiency Diseases therapy
- Abstract
Background: CD40 ligand (CD40L) deficiency, an X-linked primary immunodeficiency, causes recurrent sinopulmonary, Pneumocystis and Cryptosporidium species infections. Long-term survival with supportive therapy is poor. Currently, the only curative treatment is hematopoietic stem cell transplantation (HSCT)., Objective: We performed an international collaborative study to improve patients' management, aiming to individualize risk factors and determine optimal HSCT characteristics., Methods: We retrospectively collected data on 130 patients who underwent HSCT for CD40L deficiency between 1993-2015. We analyzed outcome and variables' relevance with respect to survival and cure., Results: Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%, and 72.3% 5 years after HSCT. Results were better in transplantations performed in 2000 or later and in children less than 10 years old at the time of HSCT. Pre-existing organ damage negatively influenced outcome. Sclerosing cholangitis was the most important risk factor. After 2000, superior OS was achieved with matched donors. Use of myeloablative regimens and HSCT at 2 years or less from diagnosis associated with higher OS and DFS. EFS was best with matched sibling donors, myeloablative conditioning (MAC), and bone marrow-derived stem cells. Most rejections occurred after reduced-intensity or nonmyeloablative conditioning, which associated with poor donor cell engraftment. Mortality occurred mainly early after HSCT, predominantly from infections. Among survivors who ceased immunoglobulin replacement, T-lymphocyte chimerism was 50% or greater donor in 85.2%., Conclusion: HSCT is curative in patients with CD40L deficiency, with improved outcome if performed before organ damage development. MAC is associated with better OS, EFS, and DFS. Prospective studies are required to compare the risks of HSCT with those of lifelong supportive therapy., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.